Medxy AI

Decoding Cellular Interactions to Enhance Neoadjuvant PD-L1 Blockade Response in Esophageal Squamous Cell Carcinoma

By MedXY 09/22/2026

This study reveals coordinated cellular programs underlying response and resistance to neoadjuvant PD-L1 blockade in ESCC, highlighting potential combinatorial immunotherapy targets for personalized treatment strategies.

Neurology news Radiology

Temporal Dynamics and Morphological Predictors of Stroke Recurrence After Craniocervical Artery Dissection

By MedXY 09/22/2026

This study delineates how vascular imaging morphologies, notably the double lumen sign, predict time-specific recurrence risk after craniocervical artery dissection, highlighting the hyperacute phase as critical for secondary prevention.

Cardiology Diabetes & Endocrinology news

Unexpected Early Postoperative Lipid Deterioration in Cushing’s Syndrome: Implications for Cardiovascular Risk and Management

By MedXY 09/22/2026

This study reveals that lipid profiles paradoxically worsen during the early remission phase after curative surgery for Cushing's syndrome, highlighting a critical window for cardiovascular risk and targeted intervention.

Cardiology news

Gene Editing Therapy in Cardiovascular Disease: Key Takeaways from the 2026 ACC Scientific Statement

By MedXY 09/22/2026

A clinician-focused summary of the 2026 ACC Scientific Statement on gene editing for cardiovascular disease, highlighting indications, recommendations, safety monitoring, ethical issues, and practical steps for integrating these therapies into practice.

Internal Medicine news Public Health

Overcoming Barriers to Medical-Legal Partnerships for Veterans Experiencing Intimate Partner Violence: Insights from the VA

By MedXY 09/22/2026

This qualitative study explores barriers and facilitators to implementing medical-legal partnerships (MLPs) for veterans experiencing intimate partner violence (IPV) within the Veterans Health Administration, highlighting critical organizational, knowledge, and systemic factors.

Clinical Updates news Rheumatology

Dapirolizumab Pegol Improves Disease Activity in Systemic Lupus Erythematosus: Evidence from Phase 3 PHOENYCS GO Trial and Prior Studies

By MedXY 09/22/2026

Dapirolizumab pegol, a CD40 ligand inhibitor, significantly improves disease activity in moderate-to-severe SLE over 48 weeks when added to standard care, supported by robust phase 3 trial data and pharmacokinetic findings.

Hematology-Oncology news

Evolving GVHD Prophylaxis in AlloHSCT: Insights from a Large Real-World Spanish Cohort

By MedXY 09/22/2026

A large Spanish study reveals the shifting landscape of GVHD prophylaxis in alloHSCT, highlighting widespread post-transplant cyclophosphamide use and its impact on acute and chronic GVHD incidence and survival outcomes.

Hematology-Oncology news Oncology

Unraveling the Risks: T-Cell Lymphoma After CAR T-Cell Therapy—A Rare but Real Concern

By MedXY 09/22/2026

T-cell lymphomas after CAR T-cell therapy are exceedingly rare but significant. This article reviews incidence, mechanisms, diagnostic challenges, and clinical implications to guide vigilance without overshadowing CAR T-cell therapy's benefits.

Hematology-Oncology news

Global Real-World Evidence Shows Survival Benefit of Maintenance Therapy Post-Autologous Stem Cell Transplant in Multiple Myeloma

By MedXY 09/22/2026

Maintenance therapies—lenalidomide, thalidomide, and bortezomib—significantly improve survival after autologous stem cell transplant for multiple myeloma, regardless of initial response status, based on a large global registry analysis.

Hematology-Oncology news Pathology & Lab Medicine

Enhancing Bone Marrow Fibrosis Diagnosis: Clinical Evaluation of AI-Driven Continuous Indexing of Fibrosis (CIF)

By MedXY 09/22/2026

This study clinically validates an AI-based quantitative tool, CIF, for bone marrow fibrosis assessment, demonstrating improved reproducibility and accuracy over manual grading without increasing assessment time.

Hematology-Oncology news Pediatrics

Targeting IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation: A Novel Therapeutic Approach in PTPN11-Mutant Juvenile Myelomonocytic Leukemia

By MedXY 09/22/2026

This study identifies an IL-17A/PTGS2/NLRP3 signaling axis as a key driver of immune suppression and myeloproliferation in PTPN11-mutant JMML, demonstrating that combined inflammasome and PTGS2 inhibition with MEK blockade improves survival and reduces leukemic burden.

Hematology-Oncology news Oncology

Targeting PKMYT1: A Promising Therapeutic Strategy for High-Risk del(17p) Multiple Myeloma

By MedXY 09/22/2026

PKMYT1 inhibition emerges as a selective and effective therapeutic approach against del(17p) high-risk multiple myeloma by inducing lethal DNA damage and mitotic failure.

Hematology-Oncology news Oncology

First-line Ibrutinib Plus Venetoclax in Nonblastoid Mantle Cell Lymphoma: Efficacy and Safety in Older Adults and TP53-Mutant Patients

By MedXY 09/22/2026

The phase 3 SYMPATICO trial demonstrated that first-line combination therapy with ibrutinib and venetoclax yields high complete response rates and durable remissions in patients ≥65 years or with TP53 mutations suffering from nonblastoid mantle cell lymphoma.

Nephrology news Respiratory

Impact of the 2023 Safety Net Policy on Kidney After Lung Transplantation: Early Changes in Transplant Practices and Outcomes

By MedXY 09/22/2026

Following the 2023 US safety net policy for kidney after lung transplantation, a shift from simultaneous lung-kidney transplants to early kidney transplantation post lung transplant was observed, with improved short-term outcomes and reduced delisting rates.

Allergy & Immunology news Respiratory

Dupilumab’s Impact on Mucus Plug Dynamics and Radiodensity in Moderate to Severe Asthma: A CT Imaging Perspective

By MedXY 09/22/2026

Dupilumab treatment in moderate to severe asthma significantly reduces mucus plug burden, resolves existing plugs, limits new plug formation, and decreases plug radiodensity on CT scans, correlating with improved lung function and ventilation.

Clinical Updates news Oncology

Patient Perceptions of Quality of Shared Decision-Making for Lung Cancer Screening in Telehealth vs In-Person Discussions: A Synthesis of Evidence and Clinical Insights

By MedXY 09/22/2026

This review synthesizes current evidence comparing patient-perceived quality of shared decision-making (SDM) for lung cancer screening (LCS) delivered via telehealth versus in-person encounters, highlighting comparable outcomes and implications for equitable access.

news Ophthalmology Public Health

Bridging the Gap in Vision Care: Insights from a CFIR-Guided Study on Community-Based Adult Eye Screening in the U.S.

By MedXY 09/22/2026

This qualitative study identifies key factors influencing the design, implementation, and sustainability of community-based adult eye screening programs in the U.S., highlighting challenges and opportunities for equitable, scalable vision screening models.

news Ophthalmology

Long-Term Recurrence of Hypertropia After Surgery in Sagging Eye Syndrome: Insights and Implications

By MedXY 09/22/2026

Strabismus surgery effectively corrects hypertropia in sagging eye syndrome (SES), yet about 25% of patients experience delayed recurrent hypertropia over two years, reflecting SES's progressive nature. Overcorrections are rare and may be confounded by fellow eye changes.

news Ophthalmology

Ultra-Widefield OCT Reveals Distinct Foveal and Optic Nerve Head Topography in Pathologic Myopia with Posterior Staphyloma

By MedXY 09/22/2026

Advanced ultra-widefield OCT mapping elucidates spatial differences in foveal and optic nerve head positioning within posterior staphyloma of pathologic myopia, highlighting distinct remodeling processes and associations with axial length and peripapillary atrophy.

Clinical Updates news Ophthalmology

Outcomes of As-Needed Aflibercept Treatment After Complete Regression in Polypoidal Choroidal Vasculopathy: A Clinical Review

By MedXY 09/22/2026

This review synthesizes evidence on PRN aflibercept treatment after complete polypoidal regression in PCV, highlighting recurrence rates, visual outcomes, and potential OCT biomarkers guiding individualized management.